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Abstract 
 
Background/Aims: Cardiovascular disease (CVD) is the leading cause of death and disability 
in the United States. The aim of this study was to assess the effect of increased utilization of 
CVD medications on MI, stroke, and all-cause mortality among different CVD risk subgroups. 
Methods:  We used 1999-2009 Medicare Current Beneficiary Survey data to identify 26,903 
non-institutionalized, fee-for-Service Medicare beneficiaries 65 years or older who were users of 
angiotensin converting enzyme inhibitor (ACE), angiotensin receptor blocker (ARB), other 
antihypertensive medications, and statin. These beneficiaries contributed a total of 61,741 
person-years. For each study drug, we used logistic regression models to estimate the effect of 
additional prescription fills on MI, stroke, and all-cause mortality; stratified according to presence 
of CVD and, in those without CVD, level of CVD risk (high versus low). 
Results:  Additional prescription fills of ACE, ARB, other antihypertensives, or statin did not 
affect MI occurrence among high CVD risk individuals; while in those with CVD, significant 
effects of ACE and statin were found: OR per 6 additional fills: 0.76 (95% CI= 0.59, 0.98) and 
0.74 (CI= 0.60, 0.92) respectively. Additional drug fills did not affect stroke in either 
subpopulation except fills of other antihypertensives in the CVD subgroup (OR of 6 additional 
fills: 0.93 (CI= 0.89, 0.98).  In both subgroups, an inverse relationship between increased use of 
the study drugs and all-cause mortality was generally found although insignificant. For those at 
lower CVD risk, events were generally too few to allow multivariate analyses. 
Conclusions: We found inverse relationships between increased use of some CVD 
medications; and MI, stroke, and mortality (although some were not significant) for some 
subpopulations but not others. Future research is needed to confirm this to justify the need to 
eliminate or reduce copays for these drugs for some subgroups that may benefit most from 
them.  
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